Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT

Overview

Journal Transplant Cell Ther

Date 2022 Mar 18

PMID 35302008

Authors

Dietlinde Wolf

Henry Barreras

Sabrina N Copsel

Krishna V Komanduri

Robert B Levy

Affiliations

Soon will be listed here.

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is complicated by graft- versus-host disease (GVHD), which causes immune dysfunction and further delays immune reconstitution through its effects on primary and secondary lymphoid organs. Treatments to prevent GVHD and improve immune recovery following allo-HSCT are needed. Post-transplantation cyclophosphamide (PTCy) is a well-established and clinically widely used method for GVHD prophylaxis after HLA-matched as well as haploidentical allo-HSCT, as well as a promising strategy in the setting of mismatched unrelated donor allo-HSCT. Recently, regulatory T cells (Tregs), a critical subset for immune homeostasis and tolerance induction, have been evaluated for use as GVHD prophylaxis in experimental models and clinical trials. Natural killer (NK) cells are one of the first lymphoid populations to reconstitute following allo-HSCT and are important mediators of protective immunity against pathogens, and are also critical for limiting post-transplantation relapse of hematologic cancers. Several reports have noted that a delay in NK cell recovery may occur following experimental mouse allo-HSCT as well as after clinical allo-HSCT. Here we examined how 2 treatment strategies, PTCy and donor expanded Tregs (TrED), in experimental MHC-matched allo-HSCT affect NK recovery. Our experiments show that both strategies improved NK cell numbers, with PTCy slightly better than TrED, early after allo-HSCT (1 month) compared with untreated allo-HSCT recipients. Importantly, NK cell IFN-γ production and cytotoxic function, as reflected by CD107 expression as well as in vivo killing of NK-sensitive tumor cells, were improved using either PTCy or TrED versus control allo-HSCT recipients. In conclusion, both prophylactic treatments were found to be beneficial for NK recovery and NK cell function following MHC-matched minor antigen-mismatched experimental allo-HSCT. Improved NK recovery could help provide early immunity toward tumors and pathogens in these transplant recipients.

Citing Articles

Graft-versus-host disease: teaching old drugs new tricks at less cost.

Farhan S, Holtan S Front Immunol. 2023; 14:1225748.

PMID: 37600820 PMC: 10435076. DOI: 10.3389/fimmu.2023.1225748.

References

Carlsten M, Jaras M . Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells. Front Immunol. 2019; 10:2357. PMC: 6797594. DOI: 10.3389/fimmu.2019.02357. View

Bunting M, Varelias A, Souza-Fonseca-Guimaraes F, Schuster I, Lineburg K, Kuns R . GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity. Blood. 2016; 129(5):630-642. PMC: 5290987. DOI: 10.1182/blood-2016-08-734020. View

Hu B, He Y, Wu Y, Bao G, Liu H, Welniak L . Activated allogeneic NK cells as suppressors of alloreactive responses. Biol Blood Marrow Transplant. 2010; 16(6):772-81. DOI: 10.1016/j.bbmt.2010.02.023. View

Luznik L, Engstrom L, Iannone R, Fuchs E . Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002; 8(3):131-8. DOI: 10.1053/bbmt.2002.v8.pm11939602. View

Simonetta F, Alvarez M, Negrin R . Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation. Front Immunol. 2017; 8:465. PMC: 5403889. DOI: 10.3389/fimmu.2017.00465. View

Gill S, Olson J, Negrin R . Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transplant. 2009; 15(7):765-76. PMC: 2884143. DOI: 10.1016/j.bbmt.2009.01.019. View

Kanakry C, ODonnell P, Furlong T, De Lima M, Wei W, Medeot M . Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014; 32(31):3497-505. PMC: 4209101. DOI: 10.1200/JCO.2013.54.0625. View

George B, Pn N, Devasia A, Kulkarni U, Korula A, Lakshmi K . Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anemia Using Matched Sibling Donors. Biol Blood Marrow Transplant. 2017; 24(3):494-500. DOI: 10.1016/j.bbmt.2017.10.034. View

Meinhardt K, Kroeger I, Bauer R, Ganss F, Ovsiy I, Rothamer J . Identification and characterization of the specific murine NK cell subset supporting graft--leukemia- and reducing graft--host-effects. Oncoimmunology. 2015; 4(1):e981483. PMC: 4368119. DOI: 10.4161/2162402X.2014.981483. View

10.

Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M . Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001; 182:18-32. DOI: 10.1034/j.1600-065x.2001.1820102.x. View

11.

Muccio L, Bertaina A, Falco M, Pende D, Meazza R, Lopez-Botet M . Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing αβ+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies. Haematologica. 2015; 101(3):371-81. PMC: 4815729. DOI: 10.3324/haematol.2015.134155. View

12.

Komanduri K, St John L, de Lima M, McMannis J, Rosinski S, McNiece I . Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007; 110(13):4543-51. PMC: 2234787. DOI: 10.1182/blood-2007-05-092130. View

13.

Ljunggren H, Ohlen C, Hoglund P, Franksson L, Karre K . The RMA-S lymphoma mutant; consequences of a peptide loading defect on immunological recognition and graft rejection. Int J Cancer Suppl. 1991; 6:38-44. DOI: 10.1002/ijc.2910470711. View

14.

Kanakry C, Tsai H, Bolanos-Meade J, Smith B, Gojo I, Kanakry J . Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014; 124(25):3817-27. PMC: 4263989. DOI: 10.1182/blood-2014-07-587477. View

15.

Luznik L, Bolanos-Meade J, Zahurak M, Chen A, Smith B, Brodsky R . High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010; 115(16):3224-30. PMC: 2858487. DOI: 10.1182/blood-2009-11-251595. View

16.

Murphy W, Bennett M, Kumar V, Longo D . Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J Immunol. 1992; 148(9):2953-60. View

17.

Hanash A, Levy R . Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood. 2004; 105(4):1828-36. DOI: 10.1182/blood-2004-08-3213. View

18.

Hefazi M, Bolivar-Wagers S, Blazar B . Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges. Int J Mol Sci. 2021; 22(18). PMC: 8469916. DOI: 10.3390/ijms22189676. View

19.

Ross D, Jones M, Komanduri K, Levy R . Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013; 19(10):1430-8. PMC: 5367157. DOI: 10.1016/j.bbmt.2013.06.019. View

20.

Wolf D, Barreras H, Bader C, Copsel S, Lightbourn C, Pfeiffer B . Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017; 23(5):757-766. PMC: 5625339. DOI: 10.1016/j.bbmt.2017.02.013. View